COUR Pharma develops first-in-class antigen-specific immune tolerance therapies using a proprietary nanoparticle platform that encapsulates disease-relevant antigens to reprogram autoimmune responses. Its lead program, CNP-103, encapsulates four recombinant proteins and is designed to induce tolerance to antigens driving type 1 diabetes; it is currently in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) in recently diagnosed adolescents and adults. COUR says the proteins in CNP-103 are believed to cover over 95% of known T1D-driving antigens and aims to prevent further islet cell destruction and preserve insulin production. The company is pursuing partnerships to advance CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis. COUR recently raised $50 million in a Series B to support the clinical advancement of CNP-103, with participation from strategic and venture investors including Lumira Ventures, Roche Venture Fund, and Sanofi.

Total raised

$185M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2026